WilmerHale Seminar: Examining New FDA Reporting Requirements

WilmerHale Seminar: Examining New FDA Reporting Requirements

Speaking Engagement
Please join us for a breakfast briefing to discuss new legal requirements imposed by the Food and Drug Administration Amendments Act of 2007 (FDAAA) for reporting clinical trial results to a public databank. These new requirements will go into effect on September 27, 2008, and entail significant penalties for non-compliance. Our discussion will be led by WilmerHale partner Scott Lassman and Robert A. Morgan, MS, JD, Senior Vice President, Regulatory Affairs & Quality/Clinical Development at Ziopharm Oncology, Inc.

We will review the requirements of the new law, the government's efforts to implement it, and also share company perspectives, including compliance approaches and challenges and potential uses for competitor intelligence gathering. The new law affects all companies sponsoring or conducting clinical research, from large pharmaceutical companies to small biotechs.

Read More About the Event

You May Be Interested In

Health Care Privacy 101 and Beyond

September 1, 2026
Speaking Engagement

Data Subject Rights: What Happens After the Request Comes In

September 8, 2026
Speaking Engagement

2026 POWER Act Webinar for District Courts in the Ninth Circuit

September 15, 2026
Speaking Engagement
View all Events

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel